As of January 3, 2020, the Independence Dosage and
Frequency Program will expand to include 11 new drugs. Most of these medical
benefit drugs are used to treat pulmonary arterial hypertension or are
biosimilars to antineoplastic agents that are already part of this program.
The following is the list of new drugs that will be added to this
program:
- Flolan® (epoprostenol sodium)
- KanjintiTM (trastuzumab-anns)
- Krystexxa® (pegloticase)
- Remodulin® (treprostinil)
- Revatio® (sildenafil)
- RuxienceTM (rituximab-pvvr)
- Tyvaso® (treprostinil)
- Veletri® (epoprostenol)
- Ventavis® (iloprost)
- Xembify® (immune globulin subcutaneous, human-klhw)
- ZirabevTM (bevacizumab-bvzr)
Learn more
For more information on the dosage and frequency guidelines, please refer to
the medical policies for each drug in the program. To access these policies,
visit our Medical
Policy Portal.
The complete list of all 71 drugs on this program can be found on our website.
If you have any questions about this program, please call the Independence
Clinical Services department at
1-800-ASK-BLUE
(1-800-275-2583).